In line with our findings, Loft et al. [10] found that the most common AEs during IL-23 inhibitor intervention were infection and nasopharyngitis, with significantly lower risks of infection and injection site reactions compared to IL-17 inhibitors use. This evidence concerns the gene IL17A and nasopharyngitis.